[
  {
    "ts": "2025-10-30T22:00:03+00:00",
    "headline": "Edwards Lifesciences (EW) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates",
    "summary": "Although the revenue and EPS for Edwards Lifesciences (EW) give a sense of how its business performed in the quarter ended September 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.",
    "url": "https://finance.yahoo.com/news/edwards-lifesciences-ew-q3-earnings-220003610.html",
    "source": "Zacks",
    "provider": "yfinance",
    "raw": {
      "id": "99c33f3c-93d3-3bd9-979d-4fc5694de250",
      "content": {
        "id": "99c33f3c-93d3-3bd9-979d-4fc5694de250",
        "contentType": "STORY",
        "title": "Edwards Lifesciences (EW) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates",
        "description": "",
        "summary": "Although the revenue and EPS for Edwards Lifesciences (EW) give a sense of how its business performed in the quarter ended September 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.",
        "pubDate": "2025-10-30T22:00:03Z",
        "displayTime": "2025-10-30T22:00:03Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/zacks.com/7853de8d69faeccb7d1ad6ebba40b8a2",
          "originalWidth": 900,
          "originalHeight": 741,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/EYdBVn9rFNc9AepqcsmXXg--~B/aD03NDE7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/7853de8d69faeccb7d1ad6ebba40b8a2.cf.webp",
              "width": 900,
              "height": 741,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/UC8YVzs0fyygH41RFBV7Qg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/7853de8d69faeccb7d1ad6ebba40b8a2.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Zacks",
          "url": "http://www.zacks.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/edwards-lifesciences-ew-q3-earnings-220003610.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/edwards-lifesciences-ew-q3-earnings-220003610.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "EW"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-10-30T20:15:00+00:00",
    "headline": "Edwards Lifesciences Announces CFO Transition Plan",
    "summary": "IRVINE, Calif., October 30, 2025--Edwards Lifesciences (NYSE: EW) today announced that Scott Ullem, the company‚Äôs chief financial officer, has decided to transition from his role by midyear 2026. While the company initiates a selection process to appoint a new CFO, this planned transition will enable continuity and a smooth transfer of responsibilities. Following the appointment of a new CFO, Ullem will continue in an advisory role.",
    "url": "https://finance.yahoo.com/news/edwards-lifesciences-announces-cfo-transition-201500651.html",
    "source": "Business Wire",
    "provider": "yfinance",
    "raw": {
      "id": "23357012-d3c4-389a-91c6-34469f4dd84b",
      "content": {
        "id": "23357012-d3c4-389a-91c6-34469f4dd84b",
        "contentType": "STORY",
        "title": "Edwards Lifesciences Announces CFO Transition Plan",
        "description": "",
        "summary": "IRVINE, Calif., October 30, 2025--Edwards Lifesciences (NYSE: EW) today announced that Scott Ullem, the company‚Äôs chief financial officer, has decided to transition from his role by midyear 2026. While the company initiates a selection process to appoint a new CFO, this planned transition will enable continuity and a smooth transfer of responsibilities. Following the appointment of a new CFO, Ullem will continue in an advisory role.",
        "pubDate": "2025-10-30T20:15:00Z",
        "displayTime": "2025-10-30T20:15:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/business-wire.com/009b07e4dcfb939c97939afd185d73d6",
          "originalWidth": 1024,
          "originalHeight": 512,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/ubkngEmVHaMz3mKQKnNwAw--~B/aD01MTI7dz0xMDI0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/009b07e4dcfb939c97939afd185d73d6.cf.webp",
              "width": 1024,
              "height": 512,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/6795bJy8BMn7q9a0XGF6OA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/009b07e4dcfb939c97939afd185d73d6.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Business Wire",
          "url": "http://www.businesswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/edwards-lifesciences-announces-cfo-transition-201500651.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/edwards-lifesciences-announces-cfo-transition-201500651.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "EW"
            },
            {
              "symbol": "META"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-10-30T20:13:00+00:00",
    "headline": "Edwards Lifesciences Reports Third Quarter Results",
    "summary": "IRVINE, Calif., October 30, 2025--Edwards Lifesciences (NYSE: EW) today reported financial results for the quarter ended September 30, 2025.",
    "url": "https://finance.yahoo.com/news/edwards-lifesciences-reports-third-quarter-201300577.html",
    "source": "Business Wire",
    "provider": "yfinance",
    "raw": {
      "id": "62fed515-f542-36e9-8d37-e505bf4c1bcf",
      "content": {
        "id": "62fed515-f542-36e9-8d37-e505bf4c1bcf",
        "contentType": "STORY",
        "title": "Edwards Lifesciences Reports Third Quarter Results",
        "description": "",
        "summary": "IRVINE, Calif., October 30, 2025--Edwards Lifesciences (NYSE: EW) today reported financial results for the quarter ended September 30, 2025.",
        "pubDate": "2025-10-30T20:13:00Z",
        "displayTime": "2025-10-30T20:13:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/business-wire.com/0085a44fd7ac9865107a85acc98645ed",
          "originalWidth": 1024,
          "originalHeight": 512,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/WbF8_jInGWQCo9cEiyqQLQ--~B/aD01MTI7dz0xMDI0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/0085a44fd7ac9865107a85acc98645ed.cf.webp",
              "width": 1024,
              "height": 512,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/wFKPwtHkIscDYrjSdGFR1A--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/0085a44fd7ac9865107a85acc98645ed.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Business Wire",
          "url": "http://www.businesswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/edwards-lifesciences-reports-third-quarter-201300577.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/edwards-lifesciences-reports-third-quarter-201300577.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "EW"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-10-30T03:14:48+00:00",
    "headline": "Why Edwards Lifesciences (EW) Is Up 7.6% After Positive Long-Term Data for SAPIEN Valve Platform",
    "summary": "In recent days, Edwards Lifesciences announced positive long-term clinical trial results for its SAPIEN TAVR technology and successful patient outcomes from real-world data on the SAPIEN M3 and EVOQUE valve systems at the annual TCT symposium. These data highlighted superior valve performance, durability, and quality-of-life improvements for patients with mitral and tricuspid valve disease, supporting Edwards‚Äô leadership in structural heart therapies. The simultaneous presentation of...",
    "url": "https://finance.yahoo.com/news/why-edwards-lifesciences-ew-7-031448790.html",
    "source": "Simply Wall St.",
    "provider": "yfinance",
    "raw": {
      "id": "e83b0315-9917-3a6d-84f1-39f961592e1e",
      "content": {
        "id": "e83b0315-9917-3a6d-84f1-39f961592e1e",
        "contentType": "STORY",
        "title": "Why Edwards Lifesciences (EW) Is Up 7.6% After Positive Long-Term Data for SAPIEN Valve Platform",
        "description": "",
        "summary": "In recent days, Edwards Lifesciences announced positive long-term clinical trial results for its SAPIEN TAVR technology and successful patient outcomes from real-world data on the SAPIEN M3 and EVOQUE valve systems at the annual TCT symposium. These data highlighted superior valve performance, durability, and quality-of-life improvements for patients with mitral and tricuspid valve disease, supporting Edwards‚Äô leadership in structural heart therapies. The simultaneous presentation of...",
        "pubDate": "2025-10-30T03:14:48Z",
        "displayTime": "2025-10-30T03:14:48Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/simply_wall_st__316/0ce3c3847d701ab519c25ddde4a069d9",
          "originalWidth": 1194,
          "originalHeight": 432,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/9u7koo0rZkPGzBeI1l4rsQ--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/0ce3c3847d701ab519c25ddde4a069d9.cf.webp",
              "width": 1194,
              "height": 432,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/5J1KBMD97NZX1sIZ71qfPg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/simply_wall_st__316/0ce3c3847d701ab519c25ddde4a069d9.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Simply Wall St.",
          "url": "https://simplywall.st/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/why-edwards-lifesciences-ew-7-031448790.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/why-edwards-lifesciences-ew-7-031448790.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "EW"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-10-30T00:14:38+00:00",
    "headline": "Why Analysts Say Edwards Lifesciences Story Is Evolving With New Data and Market Shifts",
    "summary": "Edwards Lifesciences has seen its consensus analyst price target inch higher, rising from $87.73 to $88.83 as market sentiment improves. This slight increase is supported by a mix of optimism and caution in recent analyst commentaries, driven by promising clinical data and evolving market expectations. Stay tuned to learn how you can stay ahead of shifts in the Edwards Lifesciences narrative as new information becomes available. What Wall Street Has Been Saying üêÇ Bullish Takeaways Jefferies...",
    "url": "https://finance.yahoo.com/news/why-analysts-edwards-lifesciences-story-001438795.html",
    "source": "Simply Wall St.",
    "provider": "yfinance",
    "raw": {
      "id": "fb0c144d-191b-3b3b-80ff-c27affbcdd4f",
      "content": {
        "id": "fb0c144d-191b-3b3b-80ff-c27affbcdd4f",
        "contentType": "STORY",
        "title": "Why Analysts Say Edwards Lifesciences Story Is Evolving With New Data and Market Shifts",
        "description": "",
        "summary": "Edwards Lifesciences has seen its consensus analyst price target inch higher, rising from $87.73 to $88.83 as market sentiment improves. This slight increase is supported by a mix of optimism and caution in recent analyst commentaries, driven by promising clinical data and evolving market expectations. Stay tuned to learn how you can stay ahead of shifts in the Edwards Lifesciences narrative as new information becomes available. What Wall Street Has Been Saying üêÇ Bullish Takeaways Jefferies...",
        "pubDate": "2025-10-30T00:14:38Z",
        "displayTime": "2025-10-30T00:14:38Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/simply_wall_st__316/0ce3c3847d701ab519c25ddde4a069d9",
          "originalWidth": 1194,
          "originalHeight": 432,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/9u7koo0rZkPGzBeI1l4rsQ--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/0ce3c3847d701ab519c25ddde4a069d9.cf.webp",
              "width": 1194,
              "height": 432,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/5J1KBMD97NZX1sIZ71qfPg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/simply_wall_st__316/0ce3c3847d701ab519c25ddde4a069d9.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Simply Wall St.",
          "url": "https://simplywall.st/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/why-analysts-edwards-lifesciences-story-001438795.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/why-analysts-edwards-lifesciences-story-001438795.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "EW"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]